Zuprevo - Rx 250 mL

RX Required
Requires Valid Prescription.

This product cannot be sold/shipped outside of wholesale jurisdiction. See shipping policy for more details.
In stock

Zuprevo - Rx 250 mL

Zuprevo 180 mg/ml is licensed for the treatment and prevention of bovine respiratory disease (BRD) associated with M. haemolytica, P. multocida and H.somni sensitive to tildipirosin. Zuprevo contains the active tildipirosin – a 16-membered tribasic macrolide antibiotic unique to MSD Animal Health. Zuprevo offers real world benefits - the 180 mg/ml easily syringed solution for injection specifically developed for cattle, delivers a fast and long acting macrolide in a small dose volume. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni.

Tildipirosin is a 16-member semi-synthetic macrolide antibiotic. It differs from many other macrolides by a significant duration of action after a single injection. The action of macrolides is mainly bacteriostatic, although it can be bactericidal in relation to certain pathogens. They inhibit the biosynthesis of bacterial proteins by selectively binding to bacterial ribosomal RNA and blocking the process of building a peptide chain. The spectrum of antimicrobial activity of tildipirosin includes: Mannheimia haemolitica, Pasteurella multocida, and Histophilus somni, bacterial pathogens involved in swine respiratory disease (SRD). In vitro, the effect of tildipirosin on P. multocida is bacteriostatic, and on M. haemolitica and N. somni it is bactericidal. The maximum concentration of tildipirosin in the lungs reached a maximum of 4.3 μg/g within 24 hours. and gradually decreased to 1.2 μg/g within 14 days after administration, which indicates rapid absorption of the drug by target tissues. The concentration of tildipirosin in the bronchial fluid was 14.3 μg/g, 7.0 μg/g, and 6.5 μg/g on the 5th, 10th, and 14th days after administration, respectively. During 5 days, the maximum mean ratio of tildipirosin concentrations in lungs and plasma and bronchial fluid and plasma was 148 and 673, respectively.

Side Effect
When animals were given the maximum volume of the drug for one injection site (10 ml), the formation of small swellings at the injection sites, moderately painful on palpation (the pain passed during the day), was sometimes observed, which went away on their own within 7-16 days (rarely - up to 21 days). Pathomorphological changes at the injection site completely disappeared within 35 days.

Zuprevo - Rx 250 mL Highlights:

  • SKU: 17455
  • Manufacturer: Merck Animal Health
  • Administer 4 mg tildipirosin/kg body weight (equivalent to 1 ml/45 kg body weight) once only
  • For treatment of cattle over 450 kg body weight, divide the dose so that no more than 10 ml are injected at one site
  • The rubber stopper of the vial may be safely punctured up to 20 times. Otherwise, the use of a multiple-dose syringe is recommended
  • To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing
  • It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 2 to 3 days after injection
  • If clinical signs of respiratory disease persist or increase, treatment should be changed using another antibiotic, and continued until clinical signs have resolved
More Information
SKU 17455
Manufacturer Merck Animal Health
Volume (ML) 250 ML
Species Calf, Cattle
SDS Click Here
Product Label Click Here
Write Your Own Review
You're reviewing:Zuprevo - Rx 250 mL